(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Actress and comedian Amy Schumer said she took Ozempic three years ago and quickly lost 30 lbs. However, she quit the ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

In an era where health and wellness take precedence in our daily lives, the quest for an effective and natural weight loss supplement has never been more significant. Energysyl emerges as a potential ...